TheraRadar
← Back
Data updated: Jun 28, 2026

LOTUS PHARM CO LTD

Generics

LOTUS PHARM CO LTD is a generic drug manufacturer focused on Neurology.

2010
Since
6
Drugs
-
Trials
0
New Drugs (2yr)

LOTUS PHARM CO LTD's Key Drugs

LOTUS PHARM CO LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LOTUS PHARM CO LTD's Recent FDA Approvals

New NDA/BLA approvals for LOTUS PHARM CO LTD over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LOTUS PHARM CO LTD's Therapeutic Areas

LOTUS PHARM CO LTD's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
1 drugs

LOTUS PHARM CO LTD's Top Competitors

LOTUS PHARM CO LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LOTUS PHARM CO LTD Pipeline Snapshot

Active clinical trials for LOTUS PHARM CO LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling